BR0011680A - Agonistas receptores de somatostatina neuromedina b, seu uso e composição farmacêutica compreendendo os mesmos - Google Patents
Agonistas receptores de somatostatina neuromedina b, seu uso e composição farmacêutica compreendendo os mesmosInfo
- Publication number
- BR0011680A BR0011680A BR0011680-7A BR0011680A BR0011680A BR 0011680 A BR0011680 A BR 0011680A BR 0011680 A BR0011680 A BR 0011680A BR 0011680 A BR0011680 A BR 0011680A
- Authority
- BR
- Brazil
- Prior art keywords
- neuromedin
- pharmaceutical composition
- same
- receptor agonists
- somatostatin receptor
- Prior art date
Links
- 229940127504 Somatostatin Receptor Agonists Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- RWBLWXCGQLZKLK-USVTTYPOSA-N (2s)-2-[(2-aminoacetyl)amino]-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxob Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CN)C(C)C)C1=CN=CN1 RWBLWXCGQLZKLK-USVTTYPOSA-N 0.000 title 1
- 108010073466 Bombesin Receptors Proteins 0.000 abstract 1
- 102000052872 Neuromedin B receptors Human genes 0.000 abstract 1
- 102000005157 Somatostatin Human genes 0.000 abstract 1
- 108050001286 Somatostatin Receptor Proteins 0.000 abstract 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 abstract 1
- 229960000553 somatostatin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13765599P | 1999-06-04 | 1999-06-04 | |
| PCT/US2000/015396 WO2000075186A1 (en) | 1999-06-04 | 2000-06-05 | Neuromedin b and somatostatin receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0011680A true BR0011680A (pt) | 2002-04-30 |
Family
ID=22478469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0011680-7A BR0011680A (pt) | 1999-06-04 | 2000-06-05 | Agonistas receptores de somatostatina neuromedina b, seu uso e composição farmacêutica compreendendo os mesmos |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1189941B1 (enExample) |
| JP (3) | JP2003501443A (enExample) |
| CN (1) | CN1367793A (enExample) |
| AR (1) | AR020862A1 (enExample) |
| AU (1) | AU774096B2 (enExample) |
| BR (1) | BR0011680A (enExample) |
| CA (1) | CA2376506C (enExample) |
| CZ (1) | CZ20014297A3 (enExample) |
| ES (1) | ES2401096T3 (enExample) |
| HU (1) | HUP0202022A3 (enExample) |
| IL (1) | IL146884A0 (enExample) |
| PL (1) | PL352968A1 (enExample) |
| RU (3) | RU2263680C2 (enExample) |
| TW (1) | TWI243177B (enExample) |
| WO (1) | WO2000075186A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2433785C (en) * | 2001-01-12 | 2009-08-04 | Michael Dewitt Culler | Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| CA2450446A1 (en) * | 2001-06-25 | 2003-01-03 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R | Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof |
| US7189856B2 (en) | 2001-12-28 | 2007-03-13 | Gideon Shapiro | Non-peptide somatostatin receptor ligands |
| WO2003093830A1 (en) * | 2002-05-02 | 2003-11-13 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with neuromedin b receptor (nmb) |
| CA2647986C (en) | 2006-03-31 | 2014-07-08 | Erasmus University Medical Center Rotterdam | Compositions for tumor growth control |
| MX2008013168A (es) * | 2006-04-13 | 2008-10-27 | Sod Conseils Rech Applic | Composiciones faramaceuticas del peptido 1 similar al glucagon humano, exendina-4 y análogos de los mismos. |
| CN102083451A (zh) | 2008-06-12 | 2011-06-01 | 赛恩泰新公司 | 癌症的抑制 |
| CA2727082C (en) | 2008-06-12 | 2019-02-26 | Syntaxin Limited | Fusion proteins for use in suppression of acromegaly |
| GB0820970D0 (en) | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
| CN102341925A (zh) | 2009-04-27 | 2012-02-01 | 东芝照明技术株式会社 | 照明装置 |
| CN108659100A (zh) * | 2017-03-28 | 2018-10-16 | 上海新生源医药集团有限公司 | 具有镇痛作用的多肽及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4505897A (en) * | 1983-04-18 | 1985-03-19 | The Administrators Of The Tulane Educational Fund | Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith |
| EP0478101B1 (en) * | 1990-09-24 | 2001-08-29 | W.R. Grace & Co.-Conn. | Therapeutic use of peptides having thrombospondin-like activity |
| HU207104B (en) * | 1991-01-25 | 1993-03-01 | Biosignal Kutato Fejlesztoe Kf | Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds |
| WO1993003056A1 (en) * | 1991-08-09 | 1993-02-18 | Winfried Kolbeck | Lanthionine bridged peptides |
| US5462926A (en) * | 1992-07-27 | 1995-10-31 | Biomeasure, Inc. | Neuromedin B receptor antagonists which demonstrate selectivity |
| WO1994005310A1 (en) * | 1992-09-08 | 1994-03-17 | Centocor, Inc. | Peptide inhibitors of cellular adhesion |
| RU2128055C1 (ru) * | 1992-12-07 | 1999-03-27 | Такеда Кемикал Индастриз Лтд. | Фармацевтическая композиция замедленного высвобождения и способ ее получения |
| ATE330966T1 (de) * | 1996-12-04 | 2006-07-15 | Sod Conseils Rech Applic | Somatostatin-antagonisten |
| CA2289499C (en) * | 1997-05-13 | 2010-02-23 | Michael Anthony Cawthorne | Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome x |
| WO1999025729A1 (fr) * | 1997-11-18 | 1999-05-27 | Chugai Seiyaku Kabushiki Kaisha | Composes possedant une activite antitumorale |
-
2000
- 2000-06-05 IL IL14688400A patent/IL146884A0/xx unknown
- 2000-06-05 WO PCT/US2000/015396 patent/WO2000075186A1/en not_active Ceased
- 2000-06-05 EP EP00939563A patent/EP1189941B1/en not_active Expired - Lifetime
- 2000-06-05 PL PL00352968A patent/PL352968A1/xx not_active Application Discontinuation
- 2000-06-05 AU AU54633/00A patent/AU774096B2/en not_active Ceased
- 2000-06-05 AR ARP000102776A patent/AR020862A1/es not_active Application Discontinuation
- 2000-06-05 JP JP2001502467A patent/JP2003501443A/ja active Pending
- 2000-06-05 HU HU0202022A patent/HUP0202022A3/hu unknown
- 2000-06-05 CN CN00811215A patent/CN1367793A/zh active Pending
- 2000-06-05 RU RU2002100069/04A patent/RU2263680C2/ru not_active IP Right Cessation
- 2000-06-05 CZ CZ20014297A patent/CZ20014297A3/cs unknown
- 2000-06-05 ES ES00939563T patent/ES2401096T3/es not_active Expired - Lifetime
- 2000-06-05 BR BR0011680-7A patent/BR0011680A/pt not_active Application Discontinuation
- 2000-06-05 CA CA2376506A patent/CA2376506C/en not_active Expired - Fee Related
- 2000-06-29 TW TW089110978A patent/TWI243177B/zh active
-
2005
- 2005-05-19 RU RU2005115449/04A patent/RU2005115449A/ru not_active Application Discontinuation
- 2005-05-19 RU RU2005115448/04A patent/RU2005115448A/ru not_active Application Discontinuation
-
2008
- 2008-11-12 JP JP2008290079A patent/JP5165537B2/ja not_active Expired - Fee Related
-
2011
- 2011-12-02 JP JP2011264477A patent/JP5519622B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0202022A2 (en) | 2002-10-28 |
| JP5519622B2 (ja) | 2014-06-11 |
| TWI243177B (en) | 2005-11-11 |
| CA2376506A1 (en) | 2000-12-14 |
| CN1367793A (zh) | 2002-09-04 |
| ES2401096T3 (es) | 2013-04-16 |
| JP2009108078A (ja) | 2009-05-21 |
| AU5463300A (en) | 2000-12-28 |
| PL352968A1 (en) | 2003-09-22 |
| RU2005115449A (ru) | 2006-11-20 |
| IL146884A0 (en) | 2002-08-14 |
| EP1189941A1 (en) | 2002-03-27 |
| CZ20014297A3 (cs) | 2002-06-12 |
| RU2263680C2 (ru) | 2005-11-10 |
| JP2003501443A (ja) | 2003-01-14 |
| HUP0202022A3 (en) | 2003-10-28 |
| EP1189941B1 (en) | 2013-01-09 |
| WO2000075186A1 (en) | 2000-12-14 |
| JP2012102103A (ja) | 2012-05-31 |
| AU774096B2 (en) | 2004-06-17 |
| CA2376506C (en) | 2014-07-22 |
| RU2005115448A (ru) | 2006-11-20 |
| AR020862A1 (es) | 2002-05-29 |
| JP5165537B2 (ja) | 2013-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9803179A (pt) | Antagonistas receptores de ccr-3. | |
| BR0013597A (pt) | Compostos e métodos moduladores de receptor de androgênio | |
| BR9814880A (pt) | HormÈnios de glicoproteìna bifuncionais de cadeia única | |
| NO933482D0 (no) | N-sulfonyl-2-oksoindol-derivater som har affinitet for vasopressin- og/eller ocytocin-reseptorer | |
| ATE331726T1 (de) | Adenine-derivate | |
| BR0011680A (pt) | Agonistas receptores de somatostatina neuromedina b, seu uso e composição farmacêutica compreendendo os mesmos | |
| BRPI0417684A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| GT199700009A (es) | Terapia combinada para la osteoporosis. | |
| PT918774E (pt) | Compostos moduladores do receptor para androgenio e metodos | |
| BR0206595A (pt) | Composto, composição farmacêutica, e uso de um composto | |
| BR9911621A (pt) | Bifenil sulfonamidas como antagonista duplos de receptor de angiotensina endotelina | |
| BRPI0410933A (pt) | novos antagonistas do receptor p2x7 e seu uso | |
| PT800519E (pt) | Compostos moduladores de receptores de esteroides e metodos | |
| BRPI0312649A2 (pt) | compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos. | |
| MXPA03004549A (es) | Derivados de 3-arilindola y su uso como agonistas del receptor cb2. | |
| BR9810340A (pt) | Sìntese e uso de compostos retinóides com atividades de hormÈnio negativo e/ou antagonistas | |
| AU2003246811A8 (en) | Terphenyl derivatives, preparation thereof, compositions containing same | |
| DE60024785D1 (de) | Vanilloid-analoge die resiniferatoxin-pharmacophore enthalten als wirksame vanilloid rezeptor agonisten und analgetika, zusammensetzungen und ihre verwendung | |
| BR9913457A (pt) | Neuroproteção | |
| BR0012489A (pt) | Composto, composição farmacêutica, uso de um composto, e, kit para a contracepção masculina | |
| CO5460266A1 (es) | Novedosos analogos de la somatostatina | |
| BR0318631A (pt) | os agonistas receptores peptìdeo-1 similares ao glucagon, a preparação e o uso do mesmo | |
| NO963331L (no) | 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister | |
| DK0984963T3 (da) | Hidtil ukendte forbindelser | |
| ES2172939T3 (es) | Nuevos compuestos que son antagonistas de receptores acoplados a proteina g de 7-transmembrana (tm) de p2-purinoceptores. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |